SOURCE: Brighton Markets

November 11, 2011 09:00 ET

Europe Situation Forecasts Change -- Report Highlights Wal-Mart Stores, Inc. and Targacept, Inc.

NEW YORK, NY--(Marketwire - Nov 11, 2011) - Today, www.BrightonMarkets.com announced new reports highlighting Wal-Mart Stores, Inc. (NYSE: WMT) and Targacept, Inc. (NASDAQ: TRGT). Gain market insight with full analysis and research downloads available at www.BrightonMarkets.com/index.php?coa=WMT&cob=TRGT.

With the European Financial Stability Facility set to increase to $1.4 trillion, it marks a significant move forward to strengthen the safety net in place for Europe's most troubled countries. Private bondholders of Greek debt are settling at a 50% cut as another $180 billion in fresh aid is set to arrive, enabling banks to recapitalize at a healthy 9% reserve. Overall, these measures will bring Greece's debt burden down to 120% of GDP by 2020. An important consideration is political commitment to this road map. Currently the global community appears to be on point with ECB's initiative, an outlook that should be sufficient to support markets around current levels.

Brighton Markets is releasing new coverage on Wal-Mart Stores, Inc. for its current position within the services industry. Wal-Mart Stores, Inc. (Walmart) operates retail stores. The Company operates in three business segments: Walmart U.S., Walmart International and Sam's Club. During the fiscal year ended January 31, 2011 (fiscal 2011), the Walmart U.S. segment accounted for 62. The full research report on Wal-Mart Stores, Inc. (NYSE: WMT) is available here: www.BrightonMarkets.com/index.php?coa=WMT.

Brighton Markets has released research on Targacept, Inc. for its changing role within the healthcare industry. Targacept, Inc. is a biopharmaceutical company engaged in the design, discovery and development of neuronal nicotinic receptor (NNR) Therapeutics for the treatment of diseases and disorders of the nervous system. The Company's NNR Therapeutics target NNRs. As of December 31, 2010, it had a number of clinical-stage product candidates and preclinical programs. The full research report on Targacept, Inc. (NASDAQ: TRGT) is available here: www.BrightonMarkets.com/index.php?cob=TRGT.

About Brighton Markets
Brighton Markets was founded on the guiding principle of providing highly relevant, meaningful, and actionable information direct to investors. Across the investment spectrum, Brighton Markets shines light on today's events.

Contact Information